Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Modi, Shanu; Park, Haeseong; K. Murthy, Rashmi; Iwata, Hiroji; Tamura, Kenji; Tsurutani, Junji; Moreno‐Aspitia, Alvaro; Doi, Toshihiko; Sagara, Yasuaki; H. Redfern, Charles; E. Krop, Ian; Lee, Caleb; Fujisaki, Yoshihiko; Sugihara, Masahiro; Zhang, Lin; Shahidi, Javad; Takahashi, Shunji

doi:10.1200/jco.19.02318

Public

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Published in Journal of Clinical Oncology • Feb 14, 2020

Authors:

Shanu Modi

Haeseong Park

Rashmi K. Murthy

Abstract

PURPOSE: Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in patients ...

Subject

Medicine

Internal medicine

Trastuzumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!